- Increased cardiovascular risk in patients with rheumatoid arthritis: an overview.
Increased cardiovascular risk in patients with rheumatoid arthritis: an overview.
Acta cardiologica (2014-05-03)
Daisy Puttevils, Philip De Vusser, Piet Geusens, Jo Dens
PMID24783461
ZUSAMMENFASSUNG
Patients with established rheumatoid arthritis (RA) have a higher cardiovascular morbidity and mortality in comparison with the general population. It is considered to be an independent risk factor for cardiovascular disease. The purpose of this article is to describe the mechanisms responsible for accelerated atherogenesis in RA patients and to give an overview of the effects of different RA therapies (methotrexate, TNF antagonists and other biologicals).
MATERIALIEN
Produktnummer
Marke
Produktbeschreibung
Supelco
Methotrexat -Lösung, 1.0 mg/mL in methanol with 0.1N NaOH, ampule of 1 mL, certified reference material, Cerilliant®
Methotrexat, European Pharmacopoeia (EP) Reference Standard
Methotrexat für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard
Methotrexat für die Systemeignung, European Pharmacopoeia (EP) Reference Standard